JP Morgan Downgrades DexCom to Neutral, Lowers Price Target to $75
Portfolio Pulse from Benzinga Newsdesk
JP Morgan analyst Robbie Marcus has downgraded DexCom (NASDAQ:DXCM) from Overweight to Neutral and lowered the price target from $145 to $75.
July 26, 2024 | 10:50 am
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
JP Morgan analyst Robbie Marcus downgraded DexCom from Overweight to Neutral and significantly lowered the price target from $145 to $75.
The downgrade from Overweight to Neutral and the substantial reduction in the price target from $145 to $75 by a major financial institution like JP Morgan is likely to negatively impact investor sentiment and the stock price of DexCom in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100